tiprankstipranks
Trending News
More News >
Neuroscientific Biopharmaceuticals Ltd. (AU:NSB)
ASX:NSB
Australian Market

Neuroscientific Biopharmaceuticals Ltd. (NSB) AI Stock Analysis

Compare
2 Followers

Top Page

AU

Neuroscientific Biopharmaceuticals Ltd.

(Sydney:NSB)

Rating:54Neutral
Price Target:
Neuroscientific Biopharmaceuticals Ltd. is facing substantial financial challenges, including volatile revenue and ongoing operational inefficiencies. However, the stock shows positive technical momentum and appears undervalued, providing a mixed outlook. Investors should weigh the financial performance concerns against the potential for an undervalued investment with upside momentum.

Neuroscientific Biopharmaceuticals Ltd. (NSB) vs. iShares MSCI Australia ETF (EWA)

Neuroscientific Biopharmaceuticals Ltd. Business Overview & Revenue Model

Company DescriptionNeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.
How the Company Makes MoneyNeuroscientific Biopharmaceuticals Ltd. generates revenue primarily through the development and commercialization of its proprietary pharmaceutical products. The company's key revenue streams include licensing agreements with larger pharmaceutical companies, milestone payments, and royalties from product sales. NSB may also engage in research collaborations and partnerships with academic institutions and research organizations to advance its drug development programs. Additionally, the company might receive grants and funding from government and non-government organizations to support its research initiatives.

Neuroscientific Biopharmaceuticals Ltd. Financial Statement Overview

Summary
Neuroscientific Biopharmaceuticals Ltd. faces significant financial challenges with inconsistent revenue and profitability. While the balance sheet remains debt-free, declining cash and assets present risks. Recent positive cash flow trends provide some optimism, but the company must address operational inefficiencies to achieve sustainable growth.
Income Statement
35
Negative
Neuroscientific Biopharmaceuticals Ltd. has experienced significant revenue volatility with a sharp decline to zero revenue in the most recent year. The net profit margin has improved from negative to positive, driven by a one-time gain rather than operational improvements. However, consistent negative EBIT and EBITDA margins indicate ongoing operational challenges.
Balance Sheet
45
Neutral
The company maintains a strong equity position with no debt, reflected in a high equity ratio. However, the shrinking asset base and decreasing cash reserves signal potential liquidity issues. The company has managed liabilities effectively, but sustained negative income raises concerns about future financial stability.
Cash Flow
50
Neutral
The recent improvement in free cash flow, from negative to positive, suggests improved cash management. However, the operating cash flow remains low relative to net income gains, indicating underlying operational inefficiencies. The positive trend in free cash flow is a promising sign for potential recovery.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue0.002.28M4.95M0.00958.77K0.00
Gross Profit-48.91K2.19M4.89M-64.92K897.36K-56.66K
EBITDA1.19M-1.80M-5.96M-10.37M-3.12M-2.81M
Net Income1.19M324.21K-1.07M-10.44M-3.18M-2.87M
Balance Sheet
Total Assets5.01M5.44M5.29M7.74M14.83M3.74M
Cash, Cash Equivalents and Short-Term Investments4.49M4.95M4.91M7.22M14.16M3.29M
Total Debt0.000.000.000.000.000.00
Total Liabilities26.00K85.68K597.36K2.22M223.41K88.53K
Stockholders Equity4.98M5.35M4.69M5.52M14.60M3.65M
Cash Flow
Free Cash Flow1.16M42.43K-2.30M-6.95M-2.63M-2.28M
Operating Cash Flow1.16M44.25K-2.30M-6.94M-2.60M-2.28M
Investing Cash Flow0.00-1.81K0.00-3.87K-29.88K-2.38K
Financing Cash Flow0.000.000.000.0013.51M960.80K

Neuroscientific Biopharmaceuticals Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.08
Price Trends
50DMA
0.06
Positive
100DMA
0.05
Positive
200DMA
0.04
Positive
Market Momentum
MACD
<0.01
Negative
RSI
62.24
Neutral
STOCH
57.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NSB, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.06, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 62.24 is Neutral, neither overbought nor oversold. The STOCH value of 57.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NSB.

Neuroscientific Biopharmaceuticals Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥345.58B10.59-2.88%2.67%11.80%-6.84%
AUNSB
54
Neutral
AU$26.61M9.7626.99%51.85%
$45.67M-55.44%
$1.73M-119.28%
$63.43M-99.05%
DEA1N
$3.71M-67.69%
AURAC
54
Neutral
AU$208.49M-37.20%32.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.08
0.04
100.00%
ATGGF
Actinogen Medical
0.02
0.01
100.00%
BITRF
Biotron
0.05
0.02
66.67%
IUGNF
Imugene Limited
0.01
-0.03
-75.00%
DE:A1N
Patrys Limited
AU:RAC
Race Oncology Ltd.
1.20
-0.62
-34.07%

Neuroscientific Biopharmaceuticals Ltd. Corporate Events

NeuroScientific Biopharmaceuticals Expands with New Acquisitions and Research Initiatives
Apr 24, 2025

NeuroScientific Biopharmaceuticals Ltd has announced preparations for two IND-enabling pre-clinical studies for EmtinB, targeting advanced glaucoma. Additionally, the company is acquiring StemSmart technology from Isopogen WA, which involves the use of mesenchymal stromal cells (MSC) derived from adult human donor bone marrow to treat various serious conditions. This acquisition positions NeuroScientific to expand its offerings in the cellular medicine market, with potential impacts on markets such as Crohn’s disease and organ transplant immuno-suppressants. The company has also secured $3.5 million in funding to support these initiatives.

Neuroscientific Biopharmaceuticals Announces Proposed Securities Issue
Apr 16, 2025

Neuroscientific Biopharmaceuticals Ltd announced a proposed issue of securities, including 40 million options exercisable at $0.07 and 100 million fully paid ordinary shares. This move is expected to enhance the company’s financial resources and potentially strengthen its market position, allowing it to further its research and development efforts in the biopharmaceutical field.

NeuroScientific Biopharmaceuticals Expands into Stem Cell Therapy with StemSmart Acquisition
Apr 16, 2025

NeuroScientific Biopharmaceuticals Ltd announced its acquisition of StemSmart, a patented stem cell technology from Isopogen WA, which is expected to enhance its portfolio and position in regenerative medicine. This acquisition includes a Special Access Program for treating fistulising Crohn’s disease, with promising early results from a Phase 2 trial. The company is also raising $3.5 million to support this expansion and has proposed new appointments to its board, signaling a strategic move to leverage the growing global recognition of stem cell therapies.

NeuroScientific Biopharmaceuticals Initiates Trading Halt for Major Announcement
Apr 14, 2025

NeuroScientific Biopharmaceuticals Ltd. announced a trading halt on its securities pending an announcement related to an acquisition and capital raising. This move is significant for the company as the acquisition and capital raising are considered material to its operations, potentially impacting its market positioning and stakeholder interests.

NeuroScientific Biopharmaceuticals Reports Revenue Growth and Reduced Losses
Feb 26, 2025

NeuroScientific Biopharmaceuticals Limited reported a 5% increase in revenues for the half-year ending December 2024, while significantly reducing its loss by 70% compared to the previous period. Despite not declaring a dividend, the company improved its net tangible assets per share from 2.44 cents to 3.23 cents, indicating a stronger financial position.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 23, 2025